Evista
Work Here?
Overview
About Evista
Simplify's Rating
Why Evista is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation
Industries
Consulting
Enterprise Software
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
N/A
Simplify's Take
What believers are saying
- Q2 2026 sales reached $731 million, up 7.1%, and core growth hit 5.0%.
- Management raised 2026 guidance on August 5 to 3.5%-4.5% core growth.
- Free cash flow was $105 million in Q2, and Envista repurchased $59 million of shares.
What critics are saying
- China VBP will hit orthodontics and implants in second-half 2026, cutting prices 10%-15%.
- A 2028 convertible-note redemption after August 17, 2026 can drain cash or dilute holders.
- If China VBP pricing spreads and Spark stalls, Envista’s dental platform loses scale economics.
What makes Evista unique
- Envista’s 2026 launches span implants, aligners, and AI diagnostics across two segments.
- Nobel S Series drove competitive conversions, with over one-quarter of orders from rivals.
- Spark, DEXIS, and consumables create a full-stack dental platform competitors struggle to match.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Remote Work Options
There are no jobs for Evista right now.
Find jobs on Simplify and start your career today
We update Evista's jobs every few hours, so check again soon! Browse all jobs →
About Evista
Simplify's Rating
Why Evista is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation
Industries
Consulting
Enterprise Software
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
N/A
There are no jobs for Evista right now.
Find jobs on Simplify and start your career today
We update Evista's jobs every few hours, so check again soon! Browse all jobs →